What's Going On With Altamira Therapeutics Stock?

Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares are trading higher Thursday after the company announced highlights from its NASAR clinical trial with Bentrio nasal spray were published in video format on the social media channels of the allergology journal, "Allergy."

The Details:

Altamira's NASAR trial enrolled 100 patients who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray. The study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS), as well as its secondary efficacy endpoints.

“We are delighted to see the great results from the NASAR trial shared by Allergy, one the leading medical journals in allergology, with a large audience through its social media channels,” commented Thomas Meyer, Altamira’s CEO. 

“The concept of Bentrio as a drug-free and preservative-free spray forming an efficient protective barrier within the nasal cavity appears to resonate well with allergic rhinitis sufferers. We look forward to making the product available in additional countries and helping more patients deal with the daily burden and discomfort associated with allergic rhinitis.”

Altamira shares are moving on heavy trading volume Thursday with more than 48 million shares already changing hands in the session. According to data from Benzinga Pro, the stock’s 100-day average volume is 1.157 million shares.

Related News: Experts Predict Rise In COVID-19 Cases: Vaccine Stocks Climb

How To Buy CYTO Stock:

Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.

For example, in Altamira Therapeutics’ case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.

CYTO Price Action: According to Benzinga Pro, Altamira Therapeutics shares are up 27.3% at $1.82 at the time of publication Thursday.

Image: Shutterstock